CIK 0001746473
- Non-accelerated filer
- Smaller reporting company
PLIANT THERAPEUTICS, INC.
Sign in to watch- Ticker
- PLRX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 474272481
- Phone
- +1 650-481-6770
- Business address
- 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-06-05 | Third Rock Ventures III, L.P. 10% owner | Conversion · Series A Preferred Stock | −15,250,000 | 0 | ||
| 2020-06-05 | Exter Neil Director | Conversion | +0 | 0 | ||
| 2020-06-05 | Exter Neil Director | Conversion · Series A Preferred Stock | −0 | 0 | ||
| 2020-06-05 | Coulie Bernard President and CEO | Conversion | +25,397 | 474,317 | ||
| 2020-06-05 | Coulie Bernard President and CEO | Conversion · Series B Preferred Stock | −181,594 | 0 | ||
| 2020-04-30 | Cummings Keith Lamont Chief Financial Officer | Exercise or conversion | +19,300 | $2.08 | $40K | 19,300 |
| 2020-04-30 | Cummings Keith Lamont Chief Financial Officer | Exercise or conversion · Stock Option (right to buy) | −19,300 | 206,188 | ||
| 2020-04-30 | Coulie Bernard President and CEO | Exercise or conversion | +613 | $6.22 | $4K | 613 |
| 2020-04-30 | Coulie Bernard President and CEO | Exercise or conversion | +48,227 | $2.08 | $100K | 48,840 |
| 2020-04-30 | Coulie Bernard President and CEO | Exercise or conversion · Stock Option (right to buy) | −613 | 376,723 | ||
| 2020-04-30 | Coulie Bernard President and CEO | Exercise or conversion · Stock Option (right to buy) | −48,227 | 343,380 | ||
| 2020-03-31 | Hull Hans Chief Business Officer | Grant or award · Stock Option (right to buy) | +70,352 | 70,352 | ||
| 2020-03-31 | Cummings Keith Lamont Chief Financial Officer | Grant or award · Stock Option (right to buy) | +42,841 | 42,841 | ||
| 2020-03-31 | Howes Barbara Chief Human Resource Officer | Grant or award · Stock Option (right to buy) | +7,584 | 7,584 | ||
| 2020-03-31 | Exter Neil Director | Grant or award · Stock Option (right to buy) | +26,573 | 26,573 | ||
| 2020-03-31 | Coulie Bernard President and CEO | Grant or award · Stock Option (right to buy) | +377,336 | 377,336 | ||
| 2020-02-28 | Hull Hans Chief Business Officer | Grant or award · Series C Preferred Stock | +27,322 | $13.08 | $357K | 27,322 |
| 2020-02-28 | Cummings Keith Lamont Chief Financial Officer | Grant or award · Series C Preferred Stock | +27,322 | $13.08 | $357K | 27,322 |
| 2020-02-27 | Howes Barbara Chief Human Resource Officer | Grant or award · Series C Preferred Stock | +27,322 | $13.08 | $357K | 27,322 |
Page 19 of 19 · 379 trades